RecruitingNot ApplicableNCT05715047
Intervention for Fatigue in HCT Recipients
Reducing Persistent Fatigue Following Hematopoietic Stem Cell Transplantation
Sponsor
Massachusetts General Hospital
Enrollment
66 participants
Start Date
Nov 29, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to assess whether a cognitive-behavioral therapy (CBT) for fatigue intervention is acceptable, feasible, and effective at managing fatigue and improving quality of life for patients following hematopoietic stem cell transplant (HCT).
Eligibility
Min Age: 18 Years
Inclusion Criteria7
- adult patients (≥ 18 years)
- have the ability to speak and read English
- have undergone autologous or allogeneic transplant > 6 months prior to enrollment
- no evidence of disease relapse requiring therapy
- no new other malignancy requiring therapy after transplant
- report moderate to severe fatigue in the past week (FSI average severity item rating ≥ 4 of 0-10)
- are currently receiving their care at the MGH Blood and Marrow Transplant Clinic
Exclusion Criteria4
- Patients with active cognitive impairment or uncontrolled psychiatric illness such as schizophrenia that the treating clinician believes prohibits informed consent or participation in the intervention
- Patients already receiving CBT care
- Patients living with untreated sleep apnea
- Patients with hypoxemia requiring oxygen supplementation
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BEHAVIORALCBT for Fatigue
10, individualized counseling sessions with a behavioral health counselor via Zoom platform.
BEHAVIORALUsual Care
Standard transplant care.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05715047
Related Trials
Response to Influenza Vaccination in Pediatric Oncology Patients
NCT053842881 location
Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy
NCT065794695 locations
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
NCT0640135615 locations
Clinical Study of the Safety and Efficacy of Allogeneic TCR-enhanced Vδ2 T Cell in Patients With Malignant Tumors.
NCT075705631 location
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
NCT061318015 locations